Last edition
News about "ALA-002"
PharmAla Completes GMP Manufacturing for ALA-002
PharmAla has completed GMP manufacturing of ALA-002 drug substance components and is preparing to begin GMP drug product manufacturing for upcoming global clinical trials.
ALA-002 | 07/07/2026 | By News Bureau
PharmAla Biotech Australia Ties Up with UK CDMO to Manufacture ALA-002
PharmAla Biotech Australia has contracted a UK-based CDMO to manufacture the drug substance for ALA-002, its patented non-racemic MDMA formulation, ahead of planned phase 2a/2b clinical trials for social anxiety disorder expected to begin in 2026.
ALA-002 | 16/12/2025 | By News Bureau | 255
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy